Annual Report 2008

Annual Report 2008 年報 25 於年度內，本集團與銀行簽訂了為期三個月至 一年的約人民幣 283,200,000 元的結構性存款。 該結構性存款的預期年固定利率範圍為 2.4% 至 7.0% 。截止於二零零八年十二月三十一日止， 按公允值計入損益之金融資產的價值約為人民幣 291,100,000 元。年結日後至本報告報發之日， 該結構性存款本金約人民幣 139,000,000 元已經 收回。餘額將於二零零九年內收回。對於公司仍 持有且未到期的理財產品，公司已獲得所有銀行 出具保證資金本金安全的補充協議書，確保理財 本金及預期收益率的安全。今後，公司仍會與信 譽良好的境內中資銀行開展理財業務合作，並保 證所有的理財產品都屬保本性質。 於二零零八年二月份集團在新加坡成立新公司， 名為舜宇儀器新加坡有限公司，負責三維光學影 像測量儀及顯微干涉儀等高端光學儀器的研發； 這些產品主要用於工業測量和檢查。所有項目正 依計劃正常進展。 本集團於二零零八年在中國投資設立江蘇舜宇醫 療器械有限公司，主要業務是生產及銷售醫療內 窺鏡。 於 二 零 零 八 年 十 二 月 本 集 團 以 約 人 民 幣 20,700,000 元增資力量光學有限公司股權。 增資後本集團的持股權從原來的 8.56% 上升至 54.92% 。收購力量光學將增加集團在高端光學鏡 頭領域的研發能力，並以此更好的擴大在高端手 機鏡頭及照相模組領域的市場份額。 本公司計劃運用全球發售所得款項中約人民幣 275,000,000 元提升生產能力和產能；約人民幣 173,000,000 元用於加強研發活動和設施；約人 民幣 28,000,000 元用於收購舜宇集團有限公司租 用作為生產及研發光學儀器之土地及上蓋物業； 約人民幣 25,000,000 元用於提升資訊管理系統； 約人民幣 130,000,000 元用於償還作為營運資金 的短期銀行貸款；餘額用作營運資金和其他一般 企業用途。 The Group entered into several contracts of structured deposits with banks for period from 3 months to 1 year amounting to RMB283.2 million during the year. The expected return rates stated in the contracts are fixed and ranged from 2.4% to 7.0% per annum. The value of FVTPL was approximately RMB291.1 million as of 31 December 2008. Subsequent to year end and up to the date of this report, the principal of structured deposits amounting to RMB139.0 million have been received. The remaining will be settled during the year of 2009. For the outstanding financial products, the Company has obtained all banks to issue supplementary agreements to guarantee the safety of the capital fund and to ensure the security of capital and the expected yield. In the future, the Company will continue to work with the reputable local China banks to develop the management of the Company’s financial assets. We will ensure that all of the financial products are principal-protected. In February 2008, the Group had set up a new company in Singapore, namely Sunny Instruments Singapore PTE. Ltd., which mainly focuses on the R&D of high-end optical instruments such as 3D optical vision measuring machines and microscopic interferometers. These products are mostly used for industrial measurement and inspection. All the projects have been proceeded as planned. The Group had set up a PRC company namely Jiangsu Sunny Medical Instruments Co., Ltd in the year of 2008. Its principal activity is the production and sale of medical endoscopes. In December 2008, the Group had acquired additional equity interests of Power Optics Company Limited for consideration of approximately RMB20.7 million. The equity interest held by the Group had increased from 8.56% to 54.92%. The acquisition of Power Optics would enhance the Group’s R&D capability in hi-end optical lens sets and enlarge the market share of hi-end handset lens sets and camera modules. The Company intended to invest approximately RMB275.0 million from its Global Offering for the expansion of production capability and capacity; approximately RMB173.0 million for the enhancement of R&D activities and facilities; approximately RMB28.0 million for the acquisition of land and the buildings erected thereon, which were previously leased by Sunny Group Limited for the manufacture and R&D of optical instruments; approximately RMB25.0 million for the enhancement of information systems; approximately RMB130.0 million for the repayment of short-term bank loans for working capital. The remaining amount will provide funding for working capital and other general corporate purposes.